elapegademase elapegademase elapegademase, sold under the brand name revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-scid in children and adults. elapegademaseclinical datatrade namesrevcoviother nameselapegademase-lvlrahfs/drugs.commonographlicense data us dailymed: elapegademase routes ofadministrationintramuscularatc codel03ax21 (who) legal statuslegal status us: ℞-only identifierscas number1709806-75-6drugbankdb14712unii9r3d3y0uhskeggd11017 it is a recombinant enzyme that is administered weekly by intramuscular injection. elapegademase may interact with pegylated drugs. elapegademase-lvlr was approved by the u.s. food and drug administration (fda) in 2018. leadiant biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.